Table 1 Baseline and clinical characteristics depending of COVID-19 treatment administered.
From: Absence of relevant QT interval prolongation in not critically ill COVID-19 patients
Total (N = 219) | Hydroxychloroquine and/or azithromycin (N = 105)a | Hydroxychoroquine. azithromycin and antirretroviral (N = 114) | P value | |
|---|---|---|---|---|
Baseline characteristics no. (%) | ||||
Age, mean (SD)–yr | 63.6 (17.4) | 67.1 (19.3) | 60.3 (14.7) | .002 |
Male sex | 112 (51.1) | 46 (43.8) | 66 (57.9) | .037 |
AHT | 109 (49.8) | 55 (52.4) | 54 (47.4) | .459 |
Structural Heart Diseaseb | 33 (15.1) | 21 (20.0) | 12 (10.5) | .050 |
Obesity | 19 (8.7) | 8 (7.6) | 11 (9.6) | .594 |
ACEI/ARB | 83 (37.9) | 39 (37.1) | 44 (38.6) | .825 |
Beta blocker | 39 (17.8) | 22 (21.0) | 17 (14.9) | .243 |
Antidepressant | 36 (16.4) | 26 (24.8) | 10 (8.8) | .001 |
Clinical features no. (%) | ||||
Fever–no. (%) | 145 (66.2) | 56 (53.3) | 89 (78.1) | < .001 |
Multilobar Pneumonia–no. (%) | 135 (61.6) | 47 (44.8) | 88 (77.2) | < .001 |
Myocarditis | 0 (0) | 0 (0) | (0) | – |
Ferritin–median [IQR], ng/mL | 573.0 [205.5–1275.0] | 330.0 [170.0–514.0] | 1040.0 [394.3–2215.6] | < .001 |
Hs Troponin I, median [IQR], pg/ml | 6.1 [2.2–20.0] | 11.0 [4.0–31.0] | 4.7 [2.1–10.6] | .005 |
DD–median [IQR], mg/L | 0.9 [0.5–2.1] | 1.44 [0.65–3.9] | 0.95 [0.6–1.5] | .203 |
LDH–median [IQR], IU/L | 364.0 [271.0–458.0] | 308.0 [268.0–405.0] | 391.5 [347.5–521.3] | < .001 |
CRP–median [IQR], mg/L | 73.0 [20.0–156.0] | 52.0 [22.5–172.0] | 84.0 [39.5–177.5] | < .001 |
K + –mean (SD), mEq/L | 4.0 [3.8–4.3] | 4.0 [3.8–4.4] | 4.0 [3.8–4.3] | .494 |
Ca + 2–mean (SD), mg/dL | 9.2 [8.8–9.6] | 9.2 [8.6–9.6] | 9.2 [8.9–9.5] | .374 |
Tocilizumab–no. (%) | 11 (5.0) | 0 (0.0) | 11 (9.6) | .001 |
Antidepressant–no. (%) | 27 (12.3) | 19 (18.1) | 8 (7.0) | .013 |
Neuroleptic–no. (%) | 19 (8.7) | 14 (13.3) | 5 (4.4) | .019 |
Exitus–no. (%)*** | 15 (8.2) | 10 (14.5) | 5 (4.4) | .016 |
